Conditions: Cytomegalovirus Infections
Allocation: RANDOMIZED | Intervention model: 
Enrollment: 59
Healthy volunteers: no

Brief summary:
This observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls. Data will be collected from each participant for up to 52 weeks post transplant.

Detailed description:

Arms:
arm 1: Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant. arm 2: Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.

Interventions: intervention 1: Valganciclovir
Intervention descriptions: intervention 1: Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.

Protocol document: